These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 24188890)

  • 21. Protective effects of anti-oxidant supplementations on contrast-induced nephropathy after coronary angiography: an updated and comprehensive meta-analysis and systematic review.
    Ali-Hasan-Al-Saegh S; Mirhosseini SJ; Ghodratipour Z; Sarafan-Chaharsoughi Z; Dehghan AM; Rahimizadeh E; Shahidzadeh A; Lotfaliani MR; Sedaghat-Hamedani F; Kayvanpour E; Sabashnikov A; Popov AF
    Kardiol Pol; 2016; 74(7):610-26. PubMed ID: 26779856
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Utility of the Logistic Clinical Syntax Score in the Prediction of Contrast-Induced Nephropathy After Primary Percutaneous Coronary Intervention.
    Ozturk D; Celik O; Erturk M; Kalkan AK; Uzun F; Akturk IF; Akin F; Yildirim A
    Can J Cardiol; 2016 Feb; 32(2):240-6. PubMed ID: 26255218
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The association of PRECISE-DAPT score with development of contrast-induced nephropathy in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Çınar T; Tanık VO; Aruğaslan E; Karabağ Y; Çağdaş M; Rencüzoğulları İ; Keskin M
    Cardiovasc Interv Ther; 2019 Jul; 34(3):207-215. PubMed ID: 30191494
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trimetazidine Decreases Risk of Contrast-Induced Nephropathy in Patients With Chronic Kidney Disease: A Meta-Analysis of Randomized Controlled Trials.
    Nadkarni GN; Konstantinidis I; Patel A; Yacoub R; Kumbala D; Patel RA; Annapureddy N; Pakanati KC; Simoes PK; Javed F; Benjo AM
    J Cardiovasc Pharmacol Ther; 2015 Nov; 20(6):539-46. PubMed ID: 25715308
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty--contrast-induced nephropathy] trial.
    Patti G; Ricottini E; Nusca A; Colonna G; Pasceri V; D'Ambrosio A; Montinaro A; Di Sciascio G
    Am J Cardiol; 2011 Jul; 108(1):1-7. PubMed ID: 21529740
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Volume-to-creatinine clearance ratio in patients undergoing coronary angiography with or without percutaneous coronary intervention: implications of varying definitions of contrast-induced nephropathy.
    Capodanno D; Ministeri M; Cumbo S; Dalessandro V; Tamburino C
    Catheter Cardiovasc Interv; 2014 May; 83(6):907-12. PubMed ID: 23934631
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prediction of contrast-induced nephropathy in diabetic patients undergoing elective cardiac catheterization or PCI: role of volume-to-creatinine clearance ratio and iodine dose-to-creatinine clearance ratio.
    Worasuwannarak S; Pornratanarangsi S
    J Med Assoc Thai; 2010 Jan; 93 Suppl 1():S29-34. PubMed ID: 20364554
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of short-term moderate or high-dose rosuvastatin in preventing contrast-induced nephropathy: A meta-analysis of 15 randomized controlled trials.
    Liang M; Yang S; Fu N
    Medicine (Baltimore); 2017 Jul; 96(27):e7384. PubMed ID: 28682890
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical survey on contrast-induced nephropathy after coronary angiography.
    Wang F; Li J; Huang B; Zhao Q; Yu G; Xuan C; Wei M; Wang N
    Ren Fail; 2013 Oct; 35(9):1255-9. PubMed ID: 23944863
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nicorandil Reduces the Incidence of Contrast-Induced Nephropathy in Patients Undergoing Coronary Angiography/Intervention - Systematic Review and Meta-Analysis of Randomized Controlled Trials Including GRADE Qualification.
    Pranata R; Vania R; Alkatiri AA; Firman D; Lukito AA
    Cardiovasc Revasc Med; 2020 Sep; 21(9):1121-1127. PubMed ID: 31959562
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rosuvastatin versus atorvastatin to prevent contrast induced nephropathy in patients undergoing primary percutaneous coronary intervention (ROSA-cIN trial).
    Kaya A; Kurt M; Tanboğa IH; Işik T; Ekinci M; Aksakal E; Kaya Y; Topçu S; Sevimli S
    Acta Cardiol; 2013 Oct; 68(5):489-94. PubMed ID: 24283110
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CHA2DS2-VASC score as a preprocedural predictor of contrast-induced nephropathy among patients with chronic total occlusion undergoing percutaneous coronary intervention: a single-center experience.
    Wang Y; Zhao HW; Zhang XJ; Chen BJ; Yu GN; Hou AJ; Luan B
    BMC Cardiovasc Disord; 2019 Mar; 19(1):74. PubMed ID: 30922230
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence of contrast-induced nephropathy in patients with chronic renal insufficiency undergoing multidetector computed tomographic angiography treated with preventive measures.
    El-Hajjar M; Bashir I; Khan M; Min J; Torosoff M; DeLago A
    Am J Cardiol; 2008 Aug; 102(3):353-6. PubMed ID: 18638601
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative Effect of Contrast Media Type on the Incidence of Contrast-Induced Nephropathy: A Systematic Review and Meta-analysis.
    Eng J; Wilson RF; Subramaniam RM; Zhang A; Suarez-Cuervo C; Turban S; Choi MJ; Sherrod C; Hutfless S; Iyoha EE; Bass EB
    Ann Intern Med; 2016 Mar; 164(6):417-24. PubMed ID: 26830055
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Contrast volume to creatinine clearance ratio for the prediction of contrast-induced nephropathy in patients undergoing coronary angiography or percutaneous intervention.
    Barbieri L; Verdoia M; Marino P; Suryapranata H; De Luca G;
    Eur J Prev Cardiol; 2016 Jun; 23(9):931-7. PubMed ID: 26525064
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ACE inhibitor or angiotensin II receptor blocker use is a risk factor for contrast-induced nephropathy.
    Umruddin Z; Moe K; Superdock K
    J Nephrol; 2012; 25(5):776-81. PubMed ID: 22322819
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Red cell distribution width predicts contrast-induced nephropathy in patients undergoing percutaneous coronary intervention for acute coronary syndrome.
    Kurtul A; Yarlioglues M; Murat SN; Demircelik MB; Acikgoz SK; Ergun G; Duran M; Cetin M; Ornek E
    Angiology; 2015 May; 66(5):433-40. PubMed ID: 24834929
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of alprostadil in preventing contrast-induced nephropathy in patients undergoing percutaneous coronary intervention: A multicenter prospective randomized controlled trial.
    Liang M; Yang S; Fu N; Lu C; Tian F; Xing X; Lin W; Liu J
    Catheter Cardiovasc Interv; 2018 Mar; 91(4):742-750. PubMed ID: 29024304
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of N-acetylcysteine on cystatin C-based renal function after elective coronary angiography (ENABLE Study): a prospective, randomized trial.
    Kim BJ; Sung KC; Kim BS; Kang JH; Lee KB; Kim H; Lee MH
    Int J Cardiol; 2010 Feb; 138(3):239-45. PubMed ID: 18793808
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Risk factors of contrast-induced nephropathy in patients after coronary artery intervention].
    Zhao YY; Liu DW; Wang JS; Ouyang J; Zhang WZ; Zhang WJ; Meng JQ; Tang JM
    Zhonghua Yi Xue Za Zhi; 2012 Jun; 92(22):1547-9. PubMed ID: 22944059
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.